Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
Date:8/3/2009

MOUNTAIN VIEW, Calif., Aug. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2009.

The net loss for the quarter ended June 30, 2009 was $5.0 million, compared to $16.5 million during the same period in 2008. The net loss for the first six months of 2009 was $14.9 million, compared to $30.8 million for the first six months of 2008. As of June 30, 2009, MAP Pharmaceuticals had cash, cash equivalents, short-term investments and accounts receivables of $59.9 million.

"We are very pleased that in the first Phase 3 trial for our LEVADEX(TM) migraine therapy, all four primary endpoints were met with statistical significance," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "With these positive results in hand and our recent decision to suspend development of Unit Dose Budesonide (UDB), we are now focusing our efforts on the development of LEVADEX. We believe that LEVADEX has a differentiated profile, with the potential to provide rapid and sustained relief of migraine symptoms, and could offer benefit to many of the approximately 30 million migraine sufferers in the U.S., including many who are not helped by currently available migraine therapies. We look forward to presenting the data from our successful Phase 3 trial of LEVADEX at the 14th Congress of the International Headache Society in September."

Second Quarter and Six Month Financial Results

Revenues for the quarter and six months ended June 30, 2009 were $8.6 million and $16.1 million, respectively, compared to $0 for the same periods in 2008. The collaboration revenue to date in 2009 was due to the amortization of a $40.0 million upfront payment received in February
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... intensive effort to sterilize feral cats reduced the number of ... a new study reveals. "We investigated whether we ever ... control," Dr. Julie Levy, a professor of shelter medicine at ... a university news release. "Neutering a few cats ... "so we wanted to pick a focused area and throw ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 A national leader ... into new offices with room to grow. , Headquarters for ... to a 60,000-square-foot office building at 8516 N.W. Expressway in ... named one of the Oklahoma’s best places to work by ... The company has hired 120 in the past two years, ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Home ... of in-home care for seniors, is proud to announce ... Series. The upcoming webinar will feature Dr. Suzanne Steinbaum, ... Lenox Hill Hospital in New York City, National Spokesperson ... author. The webinar will cover the issues surrounding women ...
(Date:8/22/2014)... (HealthDay News) -- Inner city children have a higher-than-normal risk ... followed 516 inner city children in four U.S. cities -- ... until age 5 and found that at least 10 percent ... Because only the three most common types of food ... inner city youngsters with food allergies may be even higher, ...
(Date:8/22/2014)... severe disabilities and multiple chronic conditions are screened for ... or no chronic conditions, a new study has found. ... with moderate disabilities or women with only one chronic ... with the Li Ka Shing Knowledge Institute of St. ... often have other measures of social vulnerability, such as ...
Breaking Medicine News(10 mins):Health News:Neutering Project Curbed Feral Cat Population 2Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2
... cardiologists have uncovered how a specific protein,s previously unsuspected role ... diabetes. Investigators in the mouse study also have found a ... The new research, available online and published in the March ... was carried out in the laboratory of Dr. Joseph ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... U.S. federal judge to block a government mandate calling for ... they are determined to fight back and keep the rule ... we can to warn young people about the dangers of ...
... Reinberg HealthDay Reporter , THURSDAY, March 1 (HealthDay ... cutting their risk of developing the deadly skin cancer melanoma, ... vitamin A called retinol could be a protective agent against ... researchers say. "We found a protective effect from supplemental ...
... years after the first sulfa drugs helped to revolutionize ... Children,s Research Hospital scientists have determined at an atomic ... The discovery provides the basis for a new generation ... to resist and cause fewer side effects. The ...
... Winship Cancer Institute of Emory University have identified a new ... cancer. Scientists had known that the gene, which encodes ... control proliferation and division. A team led by Erwin Van ... the process by which growing cancers attract new blood vessels. ...
... and surgeons are among the first in the nation ... injecting an investigational viral vector into their tumor. The ... Company, Tocagen Inc. "This clinical trial targets glioblastoma ... said principal investigator Santosh Kesari, MD, PhD, director of ...
Cached Medicine News:Health News:Cardiologists identify mechanism that makes heart disease worse in diabetics 2Health News:U.S. Will Push to Have Graphic Warnings on Cigarettes 2Health News:U.S. Will Push to Have Graphic Warnings on Cigarettes 3Health News:Vitamin A Supplements Might Cut Melanoma Risk: Study 2Health News:Vitamin A Supplements Might Cut Melanoma Risk: Study 3Health News:Solving mystery of how sulfa drugs kill bacteria yields 21st century drug development target 2Health News:Solving mystery of how sulfa drugs kill bacteria yields 21st century drug development target 3Health News:New pathway found for regulation of blood vessel growth in cancer 2Health News:UC San Diego among first in nation to treat brain cancer with novel viral vector 2
(Date:8/21/2014)... DEERFIELD, Ill. , Aug. 21, 2014 /PRNewswire/ ... reports Baxter International Inc. today announced positive results ... BAX 855, an investigational, extended half-life recombinant factor ... ADVATE [Antihemophilic Factor (Recombinant)], which met its primary ... the prophylaxis arm compared to the on-demand arm. ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe customer ... , Managing Partner and Healthcare Industry Group Leader, has ... which recognizes the most inspiring people in the life-sciences ... in research and development, marketing, technology, creativity, strategy and ... 2006 as a partner in its leading Rosetta Consulting ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... and helix provide distal shaft column ... Construction eliminates springback and provides for ... to provide a better fit for ... ,Trimmable ends provide a custom ...
... The AMS 650™ and 600M™ malleable penile ... patientsespecially those with limited dexterity. These implants ... the patient to position them in an ... the penis rigid enough for sexual intercourse ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Medicine Products: